Novartis data at ESC Congress 2026 reinforce cardiovascular
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71…
In surprise move, FDA rejects cancer drug expected to rival Novartis therapy
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of…
How Novartis R&D is advancing the next breakthrough innovations
Novartis is moving earlier, thinking differently, and making deliberate scientific choices to tackle some of medicine’s most complex…
Oak Hill Bio to take on Ultragenyx, Ionis in Angelman syndrome
RA Capital and a fleet of other investors are putting $175 million behind Oak Hill Bio, a startup…
Novartis Fabhalta® (iptacopan) receives FDA traditional
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
Roche, Eli Lilly, Novo, gene therapy, Hansoh: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Anthropic CEO interview, Medicare, Novartis: Readout Newsletter
Happy post-fourth. Hope you had a nice extended weekend, and hi from San Francisco! Today, we’re reading about Medicare…
Vertex, Roche, KRAS, SpudCell synthetic cell: Readout Newsletter
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
Novartis in Slovenia receives two gold regional innovation awards
Novartis in Slovenia received two gold regional innovation awards at the Chamber of Commerce and Industry of Slovenia…
Summit, Novartis, Takeda, Enliven, Takeda: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Roche inks Nvidia expansion to bolster AI factory
Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia partnership…
Novo Nordisk, Pfizer, Roche, Incyte, Treeline: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…